Sotera Health (NASDAQ:SHC) Issues FY 2024 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.670-0.750 for the period, compared to the consensus earnings per share estimate of 0.720. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Sotera Health also updated its FY24 guidance to $0.67-0.75 EPS.

Analyst Ratings Changes

Several analysts recently commented on SHC shares. Barclays lifted their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Finally, Citigroup raised their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Stock Performance

Sotera Health stock traded up $0.39 during midday trading on Wednesday, hitting $15.81. The stock had a trading volume of 884,591 shares, compared to its average volume of 1,304,161. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The company has a market capitalization of $4.48 billion, a PE ratio of 112.93 and a beta of 2.08. The firm’s fifty day moving average is $15.94 and its two-hundred day moving average is $13.67.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 earnings per share. On average, research analysts forecast that Sotera Health will post 0.64 EPS for the current year.

Insider Transactions at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 55.12% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.